Last reviewed · How we verify
Brentuximab Vedotin - maintenance
At a glance
| Generic name | Brentuximab Vedotin - maintenance |
|---|---|
| Also known as | Adcetris |
| Sponsor | The Lymphoma Academic Research Organisation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma (PHASE2)
- Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL (PHASE1)
- Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance (PHASE3)
- Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine (PHASE2)
- Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients (NA)
- Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (PHASE2)
- Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma (PHASE2, PHASE3)
- BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: